On July 23–24, 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) will vote on whether to recommend seven compounded peptides under FDA PCAC review for inclusion on the 503A bulks list — the federal mechanism that authorizes patient-specific compounded prescribing. Several of those peptides are directly relevant to a Limitless patient, spanning the tissue-repair, mitochondrial, and anti-inflammatory categories.
The comment is filed on the official federal docket, FDA-2025-N-6895, on regulations.gov. The public comment window closes July 22. Comments filed by July 9 are distributed to committee members before the vote; those filed after July 9 but by July 22 are still taken into consideration by FDA. Most regenerative medicine clinics will read the result. We chose to be part of how it gets decided.
The comment makes one observation and three recommendations. The observation: for the tissue-repair and mitochondrial peptide categories, the gap between mechanism strength and human-trial size is the rule, not the exception, in compounded medicine. That is precisely why compounding pathways exist. The recommendations: include with conditions (not include / exclude binary), require per-lot certificate of analysis and stability data, and require written informed consent that states the absence of human RCT efficacy data for any peptide whose dossier does not include completed Phase II trials.
It is signed Joshua Hare, DO. It is in the docket. It is public.
Most peptide clinics will react to the July vote after it happens. Your physician chose to be in the docket before it. That is what physician-led means in practice — not in marketing.
Certain GH-axis agents left our menu in May 2026 because they are not currently legal for human compounding. Tesamorelin is the GH-axis lead. Our public posture matches what the existing rules permit — and updates within 48 hours of any FDA final rule.
Per-lot certificate of analysis. Per-lot stability data. Patient-specific, signed informed consent. These are standing practice at Limitless — and the conditions we asked the committee to require of the entire 503A system.
A 90-second physician-to-patient explanation of what PCAC is, what is on the docket, and why a small clinic in Dalton chose to be inside the regulatory conversation rather than around it.
Suggested cuts for IG / FB / GBP / LinkedIn: 90s long-form, 60s tightened to beats 1–3 + 5, 30s of beats 1 + 5.
One nuance the headline coverage skips: each day-one peptide is on the docket as two separate nominations — a free-base form and an acetate salt form. The tissue-repair, mitochondrial, and anti-inflammatory entries each appear twice. The committee can vote differently on the two salt forms of the same molecule, which is what actually determines the formulation a 503A pharmacy may compound. We track the docket at that level — see the pre-vote explainer for why it matters to your prescription, not just to a chemist.
The committee's recommendations are non-binding on FDA. But the Agency typically follows them absent a strong reason not to. Final rulemaking — the formal addition of an included substance to the 503A bulks list — usually follows the vote by 12 to 18 months.
Until then, our prescribing posture is aligned with what current rules permit, and we've publicly committed to updating it within 48 hours of any FDA final rule.
The committee does not only read filings from physicians and pharmacies. It reads comments from patients. A few hundred plain words from someone who has actually been helped by a compounded peptide — entered into the federal record — are read by the same members who vote on July 23. Comments submitted by July 9, 2026 are distributed to the committee ahead of the meeting.
You do not need a lawyer, a letterhead, or a medical background. You need about ten minutes. Here is exactly how.
Go to Regulations.gov and search "Pharmacy Compounding Advisory Committee July 2026." The meeting docket accepts public input through a green Comment button. The exact docket number is published on the FDA's July 23–24 PCAC meeting announcement, which is linked from our full filed comment.
The most persuasive comments are specific and personal — which therapy, what changed, and how a licensed physician oversaw it through labs, dosing, and follow-up. You are not arguing law. You are giving the committee the human evidence a trial cannot capture. Honest and plain beats polished.
Ask the committee to preserve a regulated 503A pathway — with safeguards — rather than push these molecules into an unregulated grey market. That is the position Dr. Hare filed. One clear ask carries further than a long letter.
You may file under your name or anonymously — your choice. When you submit, you receive a tracking number; that is your proof the comment is in the federal record. That is the entire process.
Copy this, replace the italic prompts with your own words, and paste it into the comment box. Edit it freely — a comment in your own voice carries more weight than a form letter, and identical text filed many times is typically counted once.
To the Pharmacy Compounding Advisory Committee,
I am a patient writing in support of preserving a regulated 503A compounding pathway for the peptide therapies under the committee's review.
[In two or three sentences: which therapy, what condition or goal it addressed, and how a licensed physician oversaw your care — baseline labs, dosing decisions, follow-up.]
My care was managed by a licensed physician working with a compounding pharmacy that provides certificate-of-analysis documentation for every lot. That oversight is the difference between safe, monitored treatment and an unregulated grey market.
I ask the committee to recommend including these peptides on the 503A bulks list with conditions — per-lot certificate of analysis, stability data, and patient-specific informed consent — rather than excluding them and pushing patients toward unregulated sources.
Respectfully,
[Your name, or simply "A patient" — your choice.]
The full text we filed runs nine minutes and is signed in our handwriting. It is on the research library, alongside the pre-vote explainer and the GH-axis brief that walks through the May 2026 tesamorelin substitution.
The kind of clinic that files with the FDA before a vote is the kind of clinic that asks the same questions about your protocol that we asked about an entire bulk-substance list. Comprehensive labs with functional ranges. Hormone optimization that is decided on, not guessed at. A peptide menu shaped by what the rules permit, not what the marketing says. NAD+ therapy that's structured around what the evidence supports.